Biomarin Pharmaceutical reported $4.68M in Interest Expense on Debt for its third fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Interest Expense On Debt Change
Alnylam Pharmaceuticals ALNY:US USD 41.08M 1.52M
Amgen AMGN:US USD 368M 40M
Biogen BIIB:US USD 59.9M 5.9M
Biomarin Pharmaceutical BMRN:US USD 4.68M 820K
Gilead Sciences GILD:US USD 229M 13M
Insmed INSM:US USD 3.35M 4K
Intercept Pharmaceuticals ICPT:US USD 5.24M 1.43M
IONIS PHARMACEUT IONS:US USD 2.14M 9K
Moderna Inc MRNA:US USD 8M 3M
Neurocrine Biosciences NBIX:US USD 1.2M 1000K
Ptc Therapeutics PTCT:US USD 19.48M 2.8M
Regeneron Pharmaceuticals REGN:US USD 15.3M 2.2M
Sarepta Therapeutics SRPT:US USD 14.74M 1.29M
United Therapeutics UTHR:US USD 9.2M 3M
Vertex Pharmaceuticals VRTX:US USD 13.7M 900K
YTE INCY:US USD 641K 37K